泰和诚医疗上涨2.12%，报5.3美元/股，总市值2629.71万美元

Core Insights - Taihe Cheng Medical (CCM) experienced a 2.12% increase in stock price, reaching $5.3 per share, with a total market capitalization of $26.2971 million as of August 19 [1] - For the fiscal year ending December 31, 2024, the company reported total revenue of 384 million RMB, a year-over-year decrease of 28.55%, and a net profit attributable to shareholders of -30.8 million RMB, a decrease of 3.56% [1] Company Overview - Taihe Cheng Medical Group Limited is primarily engaged in medical services and was listed on the New York Stock Exchange in 2009, with recommendations from JP Morgan, Morgan Stanley, and CICC [1] - Established in 1997, the company specializes in cancer prevention, diagnosis, education, and research, offering third-party tumor imaging diagnosis and radiation therapy services, as well as operating specialized cancer hospitals and outpatient departments [1] Strategic Partnerships - In 2015, Taihe Cheng signed a long-term strategic cooperation agreement with the University of Texas MD Anderson Cancer Center, focusing on various aspects such as diagnostic technology, radiation quality control, medical processes, operational management, and brand usage in Singapore and mainland China [1] - The collaboration aims to build an international cancer specialty hospital based on a multidisciplinary treatment model and clinical research, enhancing patient experience and improving cancer treatment standards in China [1]